American Diabetes Association Professional Practice Committee for Diabetes. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes — 2026. Diabetes Care 2026;49(Suppl 1):183-215. Abstract

André F et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: Final overall survival results from SOLAR-1. Ann Oncol 2021;32(2):208-17. Abstract

Cheung Y-MM et al. A targeted approach to phosphoinositide-3-kinase/Akt/mammalian target of rapamycin-induced hyperglycemia. Curr Probl Cancer 2022;46(1):100776. Abstract

Gallagher EJ et al. Managing hyperglycemia and rash associated with alpelisib: Expert consensus recommendations using the Delphi technique. NPJ Breast Cancer 2024;10(1):12. Abstract

Iyengar NM et al. Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: Expert opinion. NPJ Breast Cancer 2025;12(1):16. Abstract

Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract

Kotwal A et al. Patient-centered diabetes care of cancer patients. Curr Diab Rep 2021;21(12):62. Abstract

Llombart-Cussac A et al. Preventing alpelisib-related hyperglycaemia in HR+/HER2-/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): A multicentre, open-label, single-arm, phase 2 trial. EClinicalMedicine 2024:71:102520. Abstract

Rugo H et al. Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: Characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study. ESMO Open 2024;9(9):103697. Abstract

Turner NC et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med 2023;388(22):2058-70. Abstract